OxymetholoneCAS# 434-07-1 |
- A-867744
Catalog No.:BCC1324
CAS No.:1000279-69-5
- Rocuronium Bromide
Catalog No.:BCC1068
CAS No.:119302-91-9
- Rivastigmine
Catalog No.:BCC1900
CAS No.:123441-03-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 434-07-1 | SDF | Download SDF |
| PubChem ID | 5281034 | Appearance | Powder |
| Formula | C21H32O3 | M.Wt | 332.48 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO | ||
| Chemical Name | (2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxymethylidene)-10,13,17-trimethyl-1,4,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one | ||
| SMILES | CC12CCC3C(C1CCC2(C)O)CCC4C3(CC(=CO)C(=O)C4)C | ||
| Standard InChIKey | ICMWWNHDUZJFDW-DHODBPELSA-N | ||
| Standard InChI | InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Oxymetholone Dilution Calculator
Oxymetholone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0077 mL | 15.0385 mL | 30.077 mL | 60.154 mL | 75.1925 mL |
| 5 mM | 0.6015 mL | 3.0077 mL | 6.0154 mL | 12.0308 mL | 15.0385 mL |
| 10 mM | 0.3008 mL | 1.5038 mL | 3.0077 mL | 6.0154 mL | 7.5192 mL |
| 50 mM | 0.0602 mL | 0.3008 mL | 0.6015 mL | 1.2031 mL | 1.5038 mL |
| 100 mM | 0.0301 mL | 0.1504 mL | 0.3008 mL | 0.6015 mL | 0.7519 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Oxymetholone is a 17alpha -alkylated anabolic-androgenic steroid.
- Methenolone acetate
Catalog No.:BCC9028
CAS No.:434-05-9
- Ethisterone
Catalog No.:BCC4478
CAS No.:434-03-7
- VU 0357121
Catalog No.:BCC4595
CAS No.:433967-28-3
- 3-O-Acetyloleanolic acid
Catalog No.:BCN5486
CAS No.:4339-72-4
- Toddaculine
Catalog No.:BCN3639
CAS No.:4335-12-0
- Boc-Tyr-OMe
Catalog No.:BCC3459
CAS No.:4326-36-7
- 6-Hydroxykaempferol
Catalog No.:BCN3334
CAS No.:4324-55-4
- Formoterol Hemifumarate
Catalog No.:BCC4349
CAS No.:43229-80-7
- Fenbendazole
Catalog No.:BCC1236
CAS No.:43210-67-9
- Skp2 Inhibitor C1
Catalog No.:BCC6298
CAS No.:432001-69-9
- 6-(5-Chloropyridin-2-yl)-7-hydroxy-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-one
Catalog No.:BCC8753
CAS No.:43200-81-3
- Zopiclone
Catalog No.:BCC9195
CAS No.:43200-80-2
- Lithocholic Acid
Catalog No.:BCC3805
CAS No.:434-13-9
- Nandrolone
Catalog No.:BCC9086
CAS No.:434-22-0
- Dacarbazine
Catalog No.:BCC1174
CAS No.:4342-03-4
- K 41498
Catalog No.:BCC5867
CAS No.:434938-41-7
- L-5-Hydroxytryptophan
Catalog No.:BCC8106
CAS No.:4350-09-8
- H-Arg(Tos)-OH
Catalog No.:BCC2867
CAS No.:4353-32-6
- 5-Hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
Catalog No.:BCC8350
CAS No.:4354-76-1
- (-)-Curine
Catalog No.:BCN2673
CAS No.:436-05-5
- Diffractic Acid
Catalog No.:BCN8506
CAS No.:436-32-8
- Fangchinoline
Catalog No.:BCN5956
CAS No.:436-77-1
- Ajmaline
Catalog No.:BCN3867
CAS No.:4360-12-7
- JKC 363
Catalog No.:BCC6022
CAS No.:436083-30-6
Protective Effects of Royal Jelly on Oxymetholone-Induced Liver Injury in Mice.[Pubmed:27178489]
Iran Biomed J. 2016 Sep;20(4):229-34. Epub 2016 May 14.
BACKGROUND: The present study was carried out to investigate the possible protective effects of royal jelly (RJ) on Oxymetholone (OXM)-induced oxidative liver injuries in mice. METHODS: In total, 32 adult male NMRI mice were divided into four groups of eight mice each. Mice in groups 1 and 2 were orally administered 5 mg/kg/day OXM for 30 days. At the same time, mice in group 3 received RJ at a dose of 100 mg/kg/day. Saline control and RJ control groups were also included in this study. RESULTS: Administration of 5 mg/kg OXM resulted in a significant decrease in total antioxidant capacity and catalase activity, as well as a significant increase in malondialdehyde (P<0.05). In addition, OXM-administrated mice showed a slight increase in liver enzymes, including alanine amino transferase, aspartate amino transferase, and alkaline phosphatase. Although OXM caused histopathological changes in the liver, RJ could significantly improve all of the above-mentioned parameters at a dose of 100 mg/kg. CONCLUSION: The results of the present study indicated that RJ has a partially protective effect on OXM-induced liver toxicity in mice.
Protective Effect of Royal Jelly on In Vitro Fertilization (IVF) in Male Mice Treated with Oxymetholone.[Pubmed:26464831]
Cell J. 2015 Fall;17(3):569-75. Epub 2015 Oct 7.
OBJECTIVE: This study aimed to investigate the effects of royal jelly (RJ) on catalase, total antioxidant capacity and embryo development in adult mice treated with Oxymetholone (OXM). MATERIALS AND METHODS: In this exprimental study, 32 male and 96 female adult Naval Medical Research Institute (NMRI) mice (7-9 weeks of age) with a ratio of 1:3 for fertili- zation purposes were randomly divided into 4 groups as follows: i. Control group (n=8) receiving 0.1 ml/mice saline daily by gavage for 30 day, ii. RJ group (n=8) treated with RJ at a dose of 100 mg/kg daily by gavage for 30 days, iii. OXM group (n=8) receiving OXM at the dose of 5 mg/kg daily by gavage for 30 days and iv. RJ+OXM group (n=8) receiving RJ at the dose of 100 mg/kg daily by gavage concomitant with 100 mg/kg OXM adminis- tration for 30 days. RESULTS: Analysis revealed a significant reduction in catalase, total antioxidant, as well as embryo development in OXM group (P<0.05). However, RJ group showed a salient recovery in the all of the above mentioned parameters and embryo toxicity. CONCLUSION: The results of this study indicated a partially protective effect of RJ against OXM-induced embryo toxicity.
Protective effect of royal jelly on the sperm parameters and testosterone level and lipid peroxidation in adult mice treated with oxymetholone.[Pubmed:25050300]
Avicenna J Phytomed. 2014 Jan;4(1):43-52.
UNLABELLED: Objectives : The aim of the present study was to evaluate protective effect of royal jelly on sperm parameters, testosterone level, and malondialdehyde (MDA) production in mice. MATERIALS AND METHODS: Thirty-two adult male NMRI mice weighing 30+/-2 g were used. All the animals were divided into 4 groups. CONTROL GROUP: received saline 0.1 ml/mouse/day orally for 30 days. Royal jelly group (RJ): received royal jelly at dose of 100 mg/kg daily for 30 days orally. Oxymetholone group: the received Oxymetholone (OX) at dose of 5 mg/kg daily for 30 days orally. Royal jelly+Oxymetholone group: received royal jelly at dose of 100 mg/kg/day orally concomitant with OX administration. Sperm count, sperm motility, viability, maturity, and DNA integrity were analyzed. Furthermore, serum testosterone and MDA concentrations were determined. RESULTS: In Oxymetholone group, sperm count, motility as well as testosterone concentration reduced significantly (p<0.05), while significant (p<0.05) increases in immature sperm, sperm with DNA damaged, and MDA concentration were announced in Oxymetholone group in comparison with control group and Royal jelly+Oxymetholone group. RJ caused partially amelioration in all of the above- mentioned parameters in Royal Jelly+Oxymetholone group. CONCLUSION: In conclusion, RJ may be used in combination with OX to improve OX-induced oxidative stress and male infertility.
Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling.[Pubmed:25434823]
Stem Cell Reports. 2015 Jan 13;4(1):90-102.
Androgens are widely used for treating Fanconi anemia (FA) and other human bone marrow failure syndromes, but their mode of action remains incompletely understood. Aged Fancd2(-/-) mice were used to assess the therapeutic efficacy of Oxymetholone (OXM) and its mechanism of action. Eighteen-month-old Fancd2(-/-) mice recapitulated key human FA phenotypes, including reduced bone marrow cellularity, red cell macrocytosis, and peripheral pancytopenia. As in humans, chronic OXM treatment significantly improved these hematological parameters and stimulated the proliferation of hematopoietic stem and progenitor cells. RNA-Seq analysis implicated downregulation of osteopontin as an important potential mechanism for the drug's action. Consistent with the increased stem cell proliferation, competitive repopulation assays demonstrated that chronic OXM therapy eventually resulted in stem cell exhaustion. These results expand our knowledge of the regulation of hematopoietic stem cell proliferation and have direct clinical implications for the treatment of bone marrow failure.
